Fulgent Genetics Forecasts 2026 Revenue Between $330M and $340M
Fulgent Genetics (FLGT) has provided its financial outlook for 2026, projecting annual revenue in the range of $330 million to $340 million. The company also expects to narrow its non-GAAP net loss to between -$1.65 and -$1.75 per share. During the Q3 earnings call, Chairman and CEO Ming Hsieh highlighted positive clinical developments regarding the company's proprietary nano drug delivery platform. This technology is central to the development of their pipeline products, specifically FID-007 and FID-022.
Tickers: $FLGT
Topics: clinical data drug delivery platform earnings call
Read the full article at Seeking Alpha
Part of the story JELD-WEN Forecasts 2026 Revenue Between $3.1B and $3.2B Amid Soft Market Demand (2 articles)